Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06164652
Other study ID # ONZ-2023-0104
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 30, 2023
Est. completion date May 14, 2024

Study information

Verified date June 2024
Source University Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Ceriter Stride One is a certified medical device that aims to provide a better, more independent and safe gait pattern for people with neurological disorders, such as Parkinson's disease. The Stride One detects the (abnormal) gait pattern via an insole with pressure sensors and generates customised audio feedback (app), e.g. to avoid or correct Freezing or Gait (Parkinson's). To gain more insight into the accuracy of the pressure and gait recordings, we want to compare them with those of the GAITRite. The GAITRite is an electronic walking carpet with an active zone 7.32m long and 0.61m wide. The carpet has pressure sensors embedded in horizontal lines. When a person steps on the carpet, these sensors capture the pressure distribution which, with the help of an algorithm, allows the collection of parameters per time unit (including speed, step time, stride time, cadence, etc.) and space (step and stride length, step and stride width, etc.). The GAITrite is considered a gold standard for capturing temporal and spatial data related to gait pattern. Our research question can be answered by having healthy subjects step over the GAITRite with the Ceriter Stride One on, and then checking the agreement between spatiotemporal factors. Thus, after IC and recording of administrative data, healthy adults will be invited for this cross-sectional validity study of a pressure-sensitive insole (Ceriter Stride One) against the validated and reliable gold standard, the GaitRite. At intake, the informed consent is gone over and signed. The inclusion and exclusion criteria are then questioned in a short interview. Inclusion criteria are pain-free and safe walking. Exclusion criteria are pregnancy and (congenital or acquired) orthopaedic, neurological and other defects that make walking without a walking aid or orthosis (or shoe adaptation) painful, difficult and/or unsafe, Ceriter insoles are placed in the test subjects' shoes, if possible in place of their own insoles, in case of orthotics on top. Via a Bluetooth transmitter, the captured signals from the pressure sensors are transmitted to and mobile phone and then via the internet to Ceriter's data portal where they are further processed and, for the purpose of this study, made available to the researchers.Subjects then step on the walking carpet with sensors (GAITRite) with these insoles in their shoes.Both systems record the pressures and analyse the gait pattern from there. Each test subject is expected to step across the walking carpet at a comfortable pace for three full lengths and 3 lengths involving acceleration. This, fitted with the insoles, so that sufficient steps are available to average out step parameters. The aim of the study is thus to find out to what extent the spatiotemporal parameters captured with the Ceriter Stride One coincide with those of the GaitRite.


Description:

Results of previous research showed no statistically significant differences between the data from the insoles compared with those from the GAITrite.These insoles show promise for clinically assessing gait in individuals with Parkinson's disease as they offer the additional ability to collect continuous information over long periods of time and in real-world contexts.The insoles used involve a different type with different technical characteristics and provide additional opportunities for collecting continuous information over long periods of time and in real-world contexts. The study will proceed as follows : recruitment of 50 healthy adults. Appeal via flyer distributed via social media will publicise the study and appeal to voluntary interested parties.The flyer will state the inclusion criteria (healthy, 18-75, M/F/X) and exclusion criteria (being pregnant, not allowed/able to walk). For interested people who contact us, the ICF will be explained and presented for signature before the corridor tests begin. Considered steps are : (a) Give info to participant and check inclusion and exclusion criteria, sign IC b) Put on Ceriter Stride One device (place this sole in shoe, change with insole) - bilaterally c) walk over the Gaitrite (8m) with the following partims : - standing (register pressure in stance) : ("stand on the line on the mat and stand still") - start and step at a comfortable pace : 3 x ("step to the other side at a comfortable pace for you") - start and accelerate (without walking) : 3x ("step to the other side, start slowly and gradually accelerate. While doing this, keep stepping, you do not have to run.") If the first attempt does not go well, a demonstration is given in addition to standardised instruction.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date May 14, 2024
Est. primary completion date May 14, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - healthy - M/V/X - 18-80 Exclusion Criteria: - pregnancy - injuries/lesions which make walking painful or difficult

Study Design


Related Conditions & MeSH terms


Intervention

Device:
walking with Ceriter Stride One
Subjects walk on the GAITRite with the CSO insole in their shoes.

Locations

Country Name City State
Belgium Ghent University Ghent Oost-Vlaanderen

Sponsors (1)

Lead Sponsor Collaborator
University Ghent

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Jacobs D, Farid L, Ferre S, Herraez K, Gracies JM, Hutin E. Evaluation of the Validity and Reliability of Connected Insoles to Measure Gait Parameters in Healthy Adults. Sensors (Basel). 2021 Sep 30;21(19):6543. doi: 10.3390/s21196543. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary step length n centimeter 3 minutes
Primary step frequency / cadance n steps per minute 3 minutes
Primary gait speed meter per second 3 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1